Revolution Medicines, INC Form 4 insider transactions

Revolution Medicines, Inc. Director Sushil Patel reported transactions involving the acquisition of stock options and the sale of common stock under a pre-arranged 10b5-1 trading plan.

Revolution Medicines' Chief Financial Officer, Jack Anders, reported a series of stock transactions on June 24, 2026, including the acquisition of stock options and the sale of common stock.

Anthony Mancini, Chief Global Commercialization Officer at Revolution Medicines, Inc., reported a transaction involving the sale of common stock to cover tax obligations.

Mark A. Goldsmith, President and CEO of Revolution Medicines, Inc., reported a transaction involving the sale of common stock to cover tax withholding obligations.

Revolution Medicines' General Counsel, Jeff Cislini, sold 2,157 shares of common stock on June 16, 2026, to cover tax withholding obligations related to vested restricted stock units.

Revolution Medicines, Inc. reports a Form 4 filing detailing a transaction by insider Stephen Michael Kelsey.

Chief Operating Officer Margaret Horn exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Margaret A. Horn, Chief Operating Officer of Revolution Medicines, Inc., reported transactions involving the acquisition and disposition of company stock under a pre-arranged trading plan.

Chief Global Commercialization Officer Anthony Mancini exercised options and sold 3,121 shares of Revolution Medicines stock.

Revolution Medicines, Inc. reports insider transactions by Chief Global Commercialization Officer Anthony Mancini, involving stock options and restricted stock units.

Revolution Medicines CEO Mark Goldsmith exercised 120,000 stock options and sold the resulting shares under a 10b5-1 plan.

Revolution Medicines' Chief Global Commercialization Officer, Anthony Mancini, exercised stock options and subsequently sold a portion of his shares under a pre-arranged 10b5-1 trading plan.

Revolution Medicines' Chief Medical Officer, Wei Lin, sold 2,073 shares of common stock for tax withholding purposes under a pre-arranged 10b5-1 plan.

Revolution Medicines' President of R&D, Stephen Michael Kelsey, sold 4,302 shares of common stock to cover tax withholding on RSU vesting.

Revolution Medicines' CEO, Mark A. Goldsmith, sold 12,871 shares of common stock for tax withholding obligations under a pre-arranged 10b5-1 plan.

Revolution Medicines' Chief Operating Officer, Margaret A. Horn, reported a future sale of 4,583 common shares to cover tax withholding obligations related to RSU vesting.

Revolution Medicines CFO Jack Anders sold 2,753 shares of common stock to cover tax withholding on RSU vesting, as per a pre-arranged 10b5-1 plan.

Revolution Medicines' General Counsel, Jeff Cislini, reported sales of common stock totaling 2,958 shares under pre-arranged 10b5-1 plans.

Revolution Medicines' EVP of Clinical Development, Xiaolin Wang, sold 2,010 shares of common stock for $99.4804 each to cover tax withholding from RSU vesting.

Revolution Medicines Director Elizabeth M. Anderson reported gifting 15,000 common shares, transferring direct ownership to an irrevocable trust.

Revolution Medicines' EVP of Clinical Development, Xiaolin Wang, reported the acquisition of common stock and stock options as part of a pre-planned equity grant.

Revolution Medicines' Chief Medical Officer, Wei Lin, acquired 15,100 shares of common stock and 34,000 stock options, effective March 1, 2026.

Revolution Medicines' President of Research and Development, Stephen Michael Kelsey, acquired 21,100 shares of common stock and 47,600 stock options.

Revolution Medicines CEO Mark A. Goldsmith exercised stock options and sold a significant number of shares, primarily through a pre-arranged 10b5-1 trading plan.

Revolution Medicines, Inc. Chief Operating Officer Margaret A. Horn was granted 21,100 shares of common stock and options to purchase 47,600 shares.

Revolution Medicines General Counsel Jeff Cislini acquired 14,500 shares of common stock and 32,500 stock options in a pre-planned transaction.

Revolution Medicines' Chief Financial Officer, Jack Anders, was granted 20,200 shares of common stock and 45,400 stock options, effective March 1, 2026.

Revolution Medicines' President and CEO, Mark A. Goldsmith, exercised options to acquire 24,010 shares of common stock at $0.54 per share.

Revolution Medicines' General Counsel, Jeff Cislini, sold 908 shares of common stock for $115.6 per share under a pre-arranged 10b5-1 plan.

Revolution Medicines' Chief Operating Officer, Margaret Horn, reported exercising stock options and selling 75,000 shares of common stock for over $7.5 million under a pre-arranged 10b5-1 trading plan.